Lite Strategy, Inc.
LITS
NASDAQ·Healthcare·Biotechnology·Mkt cap $38.8M
$1.14
▲ +9.62%
P/E
—
Mkt Cap
$38.8M
52-Wk Range
$0.69–$3.40
52-Week Range
$0.69 - $3.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 62.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Differentiated oncology pipeline with novel mechanisms of action
- Experienced management team with deep pharmaceutical development expertise
- Strategic focus on underserved cancer indications
- Clinical-stage assets with potential for significant market opportunity
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Progression of clinical candidates through development stages
Value
Valuation data unavailable
Momentum
Hot
+52.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LITS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 28, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$4.62.
Reported EPS · last 4Q
Q2 25
-$4.62
Q1 25
-$0.55
Q4 25
-$0.40
Q3 25
-$0.39
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How LITS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.